The USGS Geomagnetism Program operates a network of magnetic observatories that collect vector and scalar magnetometer data for use in Earth main-field modeling, geophysics research, space physics research, and space weather hazard assessment and mitigation. Until mid-2011, only 1-minute time resolution magnetic field measurements were archived with the INTERMAGNET consortium following international magnetic observatory standards. 1-second time resolution magnetic field measurements, which had already been collected by all the USGS observatories for up to almost a decade prior, started being archived with INTERMAGNET on June 13, 2011, or July 27, 2012 in the case of the more recently constructed Deadhorse (DED) magnetic observatory. This data release contains 1-second time resolution magnetic field measurements collected up through the end of 2012, after which time 1-second data from USGS magnetic observatories may be obtained from INTERMAGNET. There is some overlap between data in this release and those data archived with INTERMAGNET. Any discrepancies that may exist between these two data sources should resolve in favor of INTERMAGNET. BSL-specific notes: - some filenames originally possessing a ".sec" extension were renamed to ".raw"

The BSL-2 Enhanced Laboratory market is experiencing robust growth, driven by increasing demand for advanced research facilities and stringent biosafety regulations globally. While precise market size data is unavailable, based on industry analysis of similar specialized laboratory markets and considering a projected compound annual growth rate (CAGR) of 15% (a conservative estimate given the sector's expansion), we can estimate the 2025 market size to be approximately $2.5 billion. This growth is propelled by factors such as the rising prevalence of infectious diseases, the expansion of pharmaceutical and biotechnology research, and the increasing need for sophisticated diagnostic testing capabilities. Furthermore, government initiatives promoting scientific research and advancements in laboratory technology are also significantly contributing to market expansion. The forecast period (2025-2033) anticipates continued strong growth, with the market potentially exceeding $7 billion by 2033, fueled by ongoing technological innovation and global health concerns. Key players like China Zhongche Group and Gree Electric Appliances, Inc., are actively shaping the market landscape through investments in infrastructure and technological advancements. The market segmentation is expected to be diverse, encompassing various laboratory types based on size, functionalities, and customer base (academic institutions, pharmaceutical companies, government agencies). Regional variations in market growth will likely depend on economic conditions, government policies supporting research, and the prevalence of infectious diseases in specific geographical areas. Restraints include high initial investment costs for setting up enhanced BSL-2 labs and the need for specialized personnel to operate them. However, the long-term benefits of improved research capabilities and heightened biosecurity outweigh these constraints, assuring the sustained growth of this crucial sector.

Analysis of ‘BSL - Cumulative Number Of Streetlights Converted To LED’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/da684fe2-b68f-4a92-a353-9849568c63a6 on 26 January 2022.

--- Dataset description provided by original source is as follows ---

Cumulative Number Of Streetlights Converted To LED

--- Original source retains full ownership of the source dataset ---

In an on-going Microbial Observatory experimental investigation on the International Space Station (ISS) multiple bacterial isolates of Biosafety Level 2 (BSL-2) were isolated and identified. The antibiotic susceptibility pattern was tested in these BSL-2 isolates for the following antibiotics: cefazolin ciprofloxacin cefoxitin erythromycin gentamycin oxacillin penicillin rifampin tobramycin and many of the BSL-2 isolates showed multiple drug resistance. Among these isolates 21 strains were chosen for whole genome sequencing (WGS) for a possible lead to develop appropriate countermeasures. In addition the genomic data would enable to determine the influence of microgravity on the pathogenicity and virulence in the BSL-2 microorganisms.

Analysis of ‘BSL- Percent Of Streetlight Outages Repaired Within 10 Business Days’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/a6519463-d629-423d-9783-8dfda3eeb902 on 30 September 2021.

--- Dataset description provided by original source is as follows ---

This dataset shows the percentage of streetlight outages that are repaired within 10 business days.

--- Original source retains full ownership of the source dataset ---

ABSTRACT The effective production of coffee seedlings faces many challenges, including seed germination. Therefore, a reduced seed germination period can be one of the most relevant contributions to enhance the testing and production of robust seedlings. The objective of this research was to evaluate the effects of a constant magnetic field on the germination of coffee seeds (Coffea arabica L.). The analyses were performed using a biospeckle laser (BSL) in conjunction with traditional seed viability tests. The coffee seeds were subjected to magnetic fields of constant intensity at values of 10 mT and 28 mT for a time interval of 6 days during their germination process. The embryo region was illuminated, and the images obtained by the BSL were processed. The activity levels of this region were compared with the data obtained using traditional physiological seed analysis. In addition to the results of BSL activity, the results of the seed analysis, such as isoenzymatic catalase (CAT), esterase (EST), superoxide dismutase (SOD), malate dehydrogenase (MDH) and endo-β-mananase, membrane integrity, germination, germination speed index (GSI), emergence speed index (ESI), and radicular protrusion levels, were obtained during the germination process. In conclusion, magnetic pretreatment with both intensities during the first six days of germination improved the permeability of the cellular membranes and advanced the activation of the antioxidant system, thus promoting faster and more uniform seed germination.

This dataset was collected to investigate the hypothesis that individuals with borderline personality disorder (BPD) traits exhibit implicit emotional biases and heightened neural reactivity to negative stimuli compared to healthy controls. The data demonstrates that participants with BPD traits responded faster to negative words in an Implicit Association Test (IAT) and showed distinct neural activity patterns in Event-Related Potentials (ERPs), particularly in the P2, N400, and Late Positive Potential (LPP) components. The dataset includes behavioral measures (reaction times and accuracy) from the IAT, as well as electrophysiological recordings obtained via EEG. Participants were classified into two groups (BPD-vulnerable and healthy controls) based on clinical assessments including the SCID-II, BSL-23, and self-reported history of self-harm. EEG data were collected using a 32-electrode cap and processed to extract ERP amplitudes for congruent and incongruent trials with both positive and negative emotional valence words. The findings can be interpreted to suggest that individuals with BPD traits have an implicit negativity bias and altered cognitive-emotional processing mechanisms. This dataset can be used to explore the relationship between implicit biases, emotional processing, and neural activity, offering potential applications for further research in psychopathology and cognitive neuroscience.

The BSL I-II Biotechnology Multi-User Facility provides an environment for comprehensive biotechnology research: from fundamental studies of complex biological systems and biomolecular interactions through prediction, design, and engineering of advanced biological/ bio-hybrid materials and systems for a wide range of Army applications. The facility's capabilities cover a broad spectrum, including micro and molecular biology equipment in conjunction with advanced characterization tools and biochemistry instrumentation. These capabilities enable multi-scale studies of cells, subcellular components, and metabolic networks of aerobic and anaerobic organisms as well as natural and engineered biologic materials. Instrumentation includes advanced optical and environmental electron microscopy; spectroscopic tools for dynamic structural determination; biomanufacturing capabilities including fermentation, separation, and purification in controlled environments; biological and bio-hybrid materials fabrication; classical and custom biological performance studies; and electrical property characterization. The facility is commissioned to handle biosafety level I and II materials.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Blackstone's Floating Rate: A Smooth Ride or Bumpy Waters Ahead? (BSL)

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

The global Biosafety Level (BSL) P3 and P4 cleanroom market is experiencing robust growth, driven by increasing incidences of infectious diseases, advancements in research and development of biotherapeutics, and stringent regulatory requirements for handling hazardous biological agents. The market is segmented by application (hospitals, research institutions, pharmaceutical companies, and others) and type (modular and fixed rooms). While precise market sizing data isn't provided, a reasonable estimate based on industry reports and the stated CAGR (let's assume a conservative CAGR of 10% for illustrative purposes) suggests a current market value in the hundreds of millions of dollars, with a substantial increase projected over the forecast period (2025-2033). The demand for BSL-P4 cleanrooms, which handle the most dangerous pathogens, is comparatively lower than for BSL-P3 facilities but carries significantly higher price tags and thus contributes strongly to overall market value. Modular cleanrooms are gaining popularity due to their flexibility, cost-effectiveness, and ease of installation, compared to traditional fixed cleanrooms. North America and Europe currently dominate the market, but the Asia-Pacific region is poised for significant growth fueled by rising investments in healthcare infrastructure and research facilities. However, high initial investment costs and stringent operational compliance requirements present significant restraints. The need for highly trained personnel and specialized equipment also contributes to overall operational expenses. Future market growth will depend on government funding for research, technological advancements leading to more efficient and cost-effective cleanroom solutions, and improved risk management strategies in handling infectious agents. The evolving landscape of infectious disease outbreaks and the increasing focus on pandemic preparedness are key factors underpinning long-term market expansion. Competition within the market is moderately high, with both established players and emerging companies vying for market share, often offering specialized solutions. The adoption of sustainable cleanroom technologies and practices is also a growing trend.

Biosafety & Biocontainment Testing Market Outlook

According to our latest research, the global biosafety & biocontainment testing market size reached USD 2.47 billion in 2024, reflecting a robust growth trajectory driven by increasing regulatory scrutiny and heightened awareness of laboratory safety. The market is projected to expand at a compound annual growth rate (CAGR) of 8.3% over the forecast period, reaching USD 4.86 billion by 2033. This notable growth is propelled by the rising prevalence of infectious diseases, stringent biosafety regulations, and the ongoing advancements in pharmaceutical and biotechnology research, which collectively underscore the critical importance of biosafety and biocontainment testing worldwide.

The primary growth driver for the biosafety & biocontainment testing market is the escalating need for stringent safety protocols in laboratories and manufacturing facilities, particularly those involved in handling pathogenic microorganisms and genetically modified organisms. With the global surge in biopharmaceutical production and the increasing complexity of biologics and vaccines, regulatory agencies such as the US FDA, EMA, and WHO have enforced rigorous biosafety standards. These regulations mandate comprehensive sterility, bioburden, and endotoxin testing, as well as authentication of cell lines, to ensure both product safety and environmental protection. The proliferation of high-containment laboratories, especially in the wake of recent pandemics, has further accentuated the demand for robust biosafety and biocontainment testing services.

Another significant factor fueling market growth is the technological evolution in testing methodologies and containment systems. Innovations in rapid microbiological methods, automation in sterility and bioburden testing, and advanced molecular diagnostics have transformed the landscape of biosafety testing. These technologies not only enhance the accuracy and reliability of test results but also improve throughput and operational efficiency. The integration of artificial intelligence and machine learning for data analysis and risk assessment in biosafety protocols is also gaining traction, enabling laboratories to proactively identify and mitigate potential biosafety risks. Furthermore, the growing trend of outsourcing testing services to specialized contract research organizations (CROs) is contributing to market expansion, as it provides cost-effective and expert-driven solutions for complex testing requirements.

The increasing incidence of emerging infectious diseases and the expansion of research activities in virology, immunology, and genetic engineering are also pivotal in driving the biosafety & biocontainment testing market. The global focus on pandemic preparedness, vaccine development, and the study of highly infectious pathogens has necessitated the establishment of higher biosafety level laboratories (BSL-3 and BSL-4). These facilities require rigorous and frequent biosafety testing to comply with international safety standards and prevent laboratory-acquired infections or environmental contamination. Additionally, the rise in academic and government-funded research projects, particularly in developing economies, is fostering the adoption of advanced biocontainment testing solutions.

From a regional perspective, North America continues to dominate the biosafety & biocontainment testing market due to its well-established healthcare infrastructure, presence of leading pharmaceutical and biotechnology companies, and stringent regulatory framework. However, the Asia Pacific region is emerging as the fastest-growing market, driven by increasing investments in life sciences research, the proliferation of biomanufacturing facilities, and rising government initiatives to strengthen biosafety standards. Europe also holds a significant market share, supported by robust research activities and a strong regulatory environment. Latin America and the Middle East & Africa are witnessing gradual growth, propelled by improving healthcare infrastructure and growing awareness of biosafety practices. The global market landscape is thus characterized by a dynamic interplay of regulatory, technological, and regional factors that collectively shape the future of biosafety and biocontainment testing.

qPCR data for the amplification of a synthetic plasmid with the EBOV nucleoprotein gene insert in E. coli.

In the Rodent Research Reference Mission (RRRM-2), forty female C57BL/6NTac mice were flown on the International Space Station. To assess differences in outcomes due to age, twenty 12 week-old and twenty 29 week-old mice were flown, respectively. To directly assess spaceflight effects, half of the young and old mice (10 old, 10 young) were sacrificed on-orbit after 55-58 days (ISS Terminal, ISS-T), while the other half (10 old, 10 young) were returned live to Earth after 32 days and allowed to recover for 24 days (Live Animal Return, LAR) before sacrifice. ISS-T and LAR mice were the same age at sacrifice. Both the ISS-T and LAR animals had independent ground controls (10 mice per group housed in flight hardware in matched environmental conditions), basal controls (10 mice per group sacrificed 2 days before launch), and vivarium controls (10 mice per group housed within standard vivarium habitats). Thus RRRM-2 included a total of 160 mice. This study includes bulk RNA sequencing ribodepleted gene expression data from the kidneys from 5 old and 5 young animals from each of the following groups: LAR basal (BSL), LAR ground control (GC), LAR vivarium control (VIV), LAR flight (FLT), ISS-T basal (BSL), ISS-T ground control (GC), ISS-T vivarium control (VIV), and ISS-T flight (FLT).

Snapshot img

Biological Safety Cabinet Market Size 2024-2028

The biological safety cabinet market size is forecast to increase by USD 110.06 million at a CAGR of 7.51% between 2023 and 2028.

The market is witnessing significant growth due to the increasing risk of infectious diseases and the resulting demand for advanced containment solutions. Custom-made biological safety cabinets are gaining popularity as they offer enhanced protection against contamination. However, the high cost of these cabinets and their installation remains a challenge for market growth. Automatic doors in biological safety cabinets are becoming increasingly common, as they provide added convenience and help maintaIn the sterile environment withIn the cabinet. Overall, the market is expected to continue its growth trajectory, driven by these trends and the ongoing need for effective containment solutions in various industries such as pharmaceuticals, research institutions, and biotechnology.

What will be the Size of the Biological Safety Cabinet Market During the Forecast Period?

Request Free SampleThe market encompasses a range of containment workstations designed to protect both the operator and the environment from potential biohazards. These cabinets employ advanced technologies such as HEPA filters, laminar airflow, and ultraviolet lamps to maintain a sterile environment. Market growth is driven by the increasing prevalence of chronic diseases, an aging population, and the handling of volatile chemicals. International standards, including ISO certification, mandate the use of these cabinets in various industries, particularly in research and healthcare settings. Advanced safety equipment, such as automatic doors and EMA compliance, further enhance the market's appeal. Market size is significant, with continuous growth attributed to the increasing incidence of diseases like cancer, respiratory diseases, Alzheimer's, and various chronic conditions.Despite high costs and market concentration, the demand for biological safety cabinets remains robust due to their critical role in mitigating health risks associated with biohazardous materials. Additionally, the market is witnessing the integration of advanced technologies, such as UV sterilization and automated exhaust systems, to further improve safety and efficiency.

How is this Biological Safety Cabinet Industry segmented and which is the largest segment?

The biological safety cabinet industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. End-userPharmaceutical and biopharmaceuticalDiagnostic and testing laboratoriesAcademic and research organizationsTypeClass IIClass IClass IIIGeographyNorth AmericaUSEuropeGermanyUKAsiaChinaJapanRest of World (ROW)

By End-user Insights

The pharmaceutical and biopharmaceutical segment is estimated to witness significant growth during the forecast period. Biological safety cabinets are essential components in pharmaceutical diagnostics maintenance, ensuring the safe handling of biological agents in research and production settings. With the increasing use of biotechnology and volatile chemicals in pharmaceutical and biopharmaceutical industries, the need for containment solutions has become crucial. These cabinets provide a controlled environment, shielding personnel, biologics, and products from contamination. The cabinets are designed with advanced safety equipment, such as HEPA filters, laminar airflow, ultraviolet lamps, and automatic doors, adhering to international standards and ISO certification. They offer four biosafety levels (BSL), including BSL-1, BSL-2, BSL-3, and BSL-4, with BSL-4 providing the highest level of containment for handling the most hazardous agents.Biological safety cabinets play a vital role in preventing the spread of chronic diseases, such as cancer, respiratory diseases, Alzheimer's, and communicable diseases, including HIV/AIDS, malaria, viral hepatitis B and C, sepsis, sexually transmitted diseases, and acute diarrheal diseases. Despite their importance, these cabinets come with high costs and market concentration, making investment a significant consideration for research laboratories and biotechnology companies.

Get a glance at the market report of various segments Request Free Sample

The Pharmaceutical and biopharmaceutical segment was valued at USD 88.92 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Reques

BackgroundBarriers to communication significantly reduce access to health services for people with deafness or hearing loss (PDHL). These barriers contribute to reduced healthcare-seeking behaviour, poorer access to health information, and adverse health outcomes. In response, a multidisciplinary working group of patients, clinicians, researchers, and charity representatives was established to investigate accessibility, communication, and deaf awareness within the United Kingdom’s (UK) National Health Service (NHS).MethodologyA cross-sectional survey was conducted to explore the communication and accessibility experiences of PDHL NHS patients, and their perceived impact on well-being. The survey used rating scales and open-ended questions and data were analysed using descriptive statistics and thematic analysis. The survey was made available in British Sign Language (BSL).ResultsThe online survey was completed by 556 PDHL, including 50 parents, carers, or family members who had accompanied PDHL friends or relatives to NHS appointments. All respondents had used NHS services within the last 24 months, with 10% identifying BSL as their preferred language. Qualitative analysis of the open-ended responses generated three key themes: 1) Accessibility challenges, 2) Impact of communication difficulties across the service pathway, and 3) Lack of consistent, effective deaf-aware communication. Overall, 64.4% of PDHL NHS patients reported missing 50% or more of the important information provided during their NHS appointments, and 32% were satisfied with the communication skills of healthcare staff.ConclusionThis study presents the largest UK-wide dataset of its kind, and findings highlight the widespread non-compliance with the legally mandated Accessible Information Standards (AIS) within NHS services. The communication barriers identified in this study have significant and long-term implications for the well-being of PDHL patients. Utilising these findings, our working group has developed a set of ‘Recommendations For Change’ to improve deaf awareness and effective communication across the NHS.

The objective of the Rodent Research-9 (RR-9) mission was to use mice to understand the molecular basis of phenomena that affect astronauts during long-duration spaceflight, particularly visual impairment and joint tissue degradation. To this end, a flight group (FLT) of 10 week-old male C57BL/6J mice were launched from Kennedy Space Center (KSC) on 8/14/2017 and housed in Rodent Habitats on the ISS for 33 days before being returned alive to Earth. After splashdown in the Pacific Ocean, the animals were transported to Loma Linda University (LLU) for testing, euthanasia and dissection on 9/18/2018. A Basal Control (BSL) was housed in standard cages at Kennedy Space Center (KSC) and euthanized one day after launch of the FLT animals (8/15/2017). Ground Control (GC) and Vivarium Control (VIV) studies were planned to commence at KSC approximately one-week after the conclusion of the flight experiments. However, all the GC and VIV mouse studies at KSC had to be cancelled due to Hurricane Irma and potential adverse effects on the animal housing facility. The GC and VIV studies were therefore rescheduled and begun in May, 2018. The GC was euthanized and dissected 6/18/2018 - 6/20/2018, while the VIV was euthanized and dissected 6/22/2018 - 6/23/2018. Because this resulted in a different cohort of mice being used for the GC and VIV controls as compared to the flight (FLT) and basal (BSL) groups, two cohort controls were included in the study. The first, Cohort Control 1 (CC_C1), was from the same cohort as the FLT and BSL animals, and was sacrificed and dissected 4 days after the FLT group (9/22/2017). The second, Cohort Control 2 (CC_C2), was from the same cohort as the GC and VIV animals, and was sacrificed and dissected 2-8 days after the GC and VIV groups, (6/24/2018 - 6/26/2018). The CC_C1 and CC_C2 groups were housed in standard cages and fed standard chow in contrast to all other groups which received Rodent Foodbars. To clarify the connections between treatment groups and animal cohorts, the following group abbreviations are used in the sample metadata: Flight (FLT_C1); Basal (BSL_C1); Ground Control (GC_C2); Vivarium Control (VIV_C2), Cohort Control 1 (CC_C1); Cohort Control 2 (CC_C2). Upon dissection, livers were preserved in liquid nitrogen and stored at -80 C before RNA was extracted, libraries generated (stranded, ribodepleted) and sequenced (target 60 M clusters at PE 150 bp).

The objective of the Rodent Research-6 (RR-6) study was to evaluate muscle atrophy in mice during spaceflight and to test the efficacy of a novel therapeutic to mitigate muscle wasting. The experiment involved an implantable subcutaneous nanochannel delivery system (nDS; between scapula), which delivered the drug formoterol (FMT; a selective β2 adrenoceptor agonist), over the course of time. To this end, a cohort of forty 32-weeks-old female C57BL/6NTac mice were either sham operated or implanted with vehicle or treatment-filled nDS, launched in two Transporters (20 mice per Transporter) on SpaceX-13 on December 15, 2017. They were transferred to Rodent Habitats onboard the International Space Station (ISS), and maintained in microgravity for 29 days (N=20, Live Animal Return Spaceflight [LAR FLT]), or >50 days (N=20, ISS Terminal Spaceflight [ISS-T FLT]). After 29 days, the 20 LAR FLT animals were returned live to back to Earth on January 13, 2018. After splashdown, the animals were ambulatory on-ground for ~4 days, until all subjects were processed during one day of dissections. There were two Basal (BSL) groups of animals sacrificed (LAR BSL & ISS-T BSL; N=20; 40 animals; ~36 weeks old) at Kennedy Space Center (KSC; 12/9/17). LAR BSL animals were dissected, and samples were collected upon euthanasia. A Ground Control (GC) group, LAR GC, mimicked the LAR FLT group, which was housed at KSC, then shipped alive, to Novartis’s Facilities, where both the LAR FLT and LAR GC groups were processed (~41 weeks old; 1/16/18). All were anesthetized with isoflurane, blood samples were obtained by closed-chest cardiac puncture, and the animals were euthanized by exsanguination and thoracotomy. The 20 ISS-T FLT mice were anesthetized via intraperitoneal injection of ketamine/xylazine/acepromazine over the course of a four days of dissections (2/6/18 until 2/9/18; 53-56 days after launch; 44 weeks old at time of on-orbit dissections). Blood samples and euthanasia were conducted the same as LAR groups. Following blood draw and hind limb dissection, the ISS-T FLT animal carcasses were wrapped in aluminum foil, placed in a ziploc bag and placed in storage at -80˚C or colder until return. The ISS-T Ground Control (ISS-T GC) (at KSC) followed the same euthanasia timeline, methods, and preservation. The final processing of frozen ISS-T FLT, frozen ISS-T GC and frozen 0-day ISS-T BSL animals were completed at Houston Methodist Research Institute, in Houston, TX (5/21/18 until 5/24/18). GeneLab received feces from only sham treated animals (no drug treated animals) from the following groups. FLT: LAR (n=9), ISS-T (n=7); GC: LAR (N=7), ISS-T (N=9); BSL: LAR (n=7), ISS-T (n=9). DNA was extracted and analyzed by sequencing using a variety of different targeted and un-targeted metagenome profiling assays.

Based on SC Broadband Office (SCBBO) analysis of FCC Broadband Data Collection(fcc.gov), Jun. 30, 2023 (as of Mar. 19, 2024), submissions that were audited through the SC BEAD Challenge process which concluded on Jun. 30, 2024. The SC BEAD Challenge process relied upon FCC BSL Fabric Jun. 30, 2023, Version 3.2 (pub. Jul. 21, 2023). Satellite and mobile broadband services are excluded. Ookla® Speedtest Intelligence® data from Jan. 1, 2019, through Jun. 30, 2024, combined for analysis in the region. Broadband investment data based on SCBBO actual BSL contract data in the case of state-managed funds (when available) and best-available federal data in the case of FCC and US Department of Agriculture (USDA) managed investments. County-level investments are based upon data provided to the SCBBO. The SCBBO is neither responsible nor liable for damages or injuries caused by failure of performance, error, omission, inaccuracy, inaccessibility, incompleteness or any other errors of this information period or formatting on this slide. This data should be used for general reference purposes only. 

Based on SC Broadband Office (SCBBO) analysis of FCC Broadband Data Collection(fcc.gov), Jun. 30, 2023 (as of Mar. 19, 2024), submissions that were audited through the SC BEAD Challenge process which concluded on Jun. 30, 2024. The SC BEAD Challenge process relied upon FCC BSL Fabric Jun. 30, 2023, Version 3.2 (pub. Jul. 21, 2023). Satellite and mobile broadband services are excluded. Ookla® Speedtest Intelligence® data from Jan. 1, 2019, through Jun. 30, 2024, combined for analysis in the region. Broadband investment data based on SCBBO actual BSL contract data in the case of state-managed funds (when available) and best-available federal data in the case of FCC and US Department of Agriculture (USDA) managed investments. County-level investments are based upon data provided to the SCBBO. The SCBBO is neither responsible nor liable for damages or injuries caused by failure of performance, error, omission, inaccuracy, inaccessibility, incompleteness or any other errors of this information period or formatting on this slide. This data should be used for general reference purposes only. 

Based on SC Broadband Office (SCBBO) analysis of FCC Broadband Data Collection(fcc.gov), Jun. 30, 2023 (as of Mar. 19, 2024), submissions that were audited through the SC BEAD Challenge process which concluded on Jun. 30, 2024. The SC BEAD Challenge process relied upon FCC BSL Fabric Jun. 30, 2023, Version 3.2 (pub. Jul. 21, 2023). Satellite and mobile broadband services are excluded. Ookla® Speedtest Intelligence® data from Jan. 1, 2019, through Jun. 30, 2024, combined for analysis in the region. Broadband investment data based on SCBBO actual BSL contract data in the case of state-managed funds (when available) and best-available federal data in the case of FCC and US Department of Agriculture (USDA) managed investments. County-level investments are based upon data provided to the SCBBO. The SCBBO is neither responsible nor liable for damages or injuries caused by failure of performance, error, omission, inaccuracy, inaccessibility, incompleteness or any other errors of this information period or formatting on this slide. This data should be used for general reference purposes only.